Lung Adenocarcinoma Harboring Triple Rare EGFR Exon 18 Mutations Rapidly Developed Resistance to Multiple Therapies.

IF 2 4区医学 Q3 ONCOLOGY

Chemotherapy Pub Date : 2022-01-01 Epub Date: 2022-06-28 DOI:10.1159/000525623

Yuyao Liu, Yuanqiang Wu, Fang Wu, Chunhong Hu

引用次数: 2

Abstract

There is no standard therapy for nonsmall-cell lung cancer harboring rare coexistent EGFR mutations. Here, we report a female patient who was diagnosed as lung adenocarcinoma with three mutations of G724S, E709K, and V689I in exon 18. The patient responded to, but also showed rapid development of resistance to multiple therapies, including a second-generation EGFR-TKI of afatinib, a platinum-based doublet chemotherapy, and a multiple target TKI of anlotinib. As such, she ended up with a short overall survival time. Further research is required to understand the resistance mechanism(s) of these complex gene mutations.

查看原文本刊更多论文

含有三种罕见EGFR外显子18突变的肺腺癌迅速对多种治疗产生耐药性。

对于含有罕见共存EGFR突变的非小细胞肺癌，目前尚无标准治疗方法。在这里，我们报告了一位女性患者，她被诊断为肺腺癌，在18号外显子中有G724S, E709K和V689I三个突变。患者对多种治疗有反应，但也显示出快速的耐药发展，包括阿法替尼的第二代EGFR-TKI，铂基双重化疗，和安洛替尼的多靶点TKI。因此，她最终的总生存时间很短。需要进一步的研究来了解这些复杂基因突变的耐药机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Chemotherapy 医学-药学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： This journal publishes original research articles and state-of-the-art reviews on all aspects of antimicrobial and antitumor chemotherapy. The results of experimental and clinical investigations into the microbiological and pharmacologic properties of antibacterial, antiviral and antitumor compounds are major topics of publication. Papers selected for the journal offer data concerning the efficacy, toxicology, and interactions of new drugs in single or combined applications. Studies designed to determine the pharmacokinetic and pharmacodynamics properties of similar preparations and comparing their efficacy are also included. Special emphasis is given to the development of drug-resistance, an increasing problem worldwide.